Screener
Jazz Pharmaceuticals JAZZ Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $1,844.3 | $1,391.9 |
| Investments | 1,030.0 | 1,050.0 |
| Accounts receivable, net of allowances | 836.3 | 830.7 |
| Inventories | 437.5 | 417.0 |
| Prepaid expenses | 149.7 | 152.5 |
| Other current assets | 285.3 | 323.9 |
| Total current assets | 4,583.1 | 4,166.0 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's accounts receivable?
- Jazz Pharmaceuticals (JAZZ) reported accounts receivable of $836.3M in Q1 2026.
- How has Jazz Pharmaceuticals's accounts receivable changed year-over-year?
- Jazz Pharmaceuticals's accounts receivable increased by 28.1% year-over-year, from $652.99M to $836.3M.
- What is the long-term trend for Jazz Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accounts receivable has grown at a 15.9% compound annual growth rate (CAGR), from $396.49M to $830.7M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Jazz Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude